All In MedTech

FDA Clearance Tracker · P060038-S020

MITROFLOW AORTIC PERICARDIAL HEART VALVE WITH PHOSPHOLIPID REDUCTION TREATMENT, MODEL DL

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 15, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 15, 2014

Approved

Time to decision

60 days

Received May 16, 2014. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P060038-S020
Device name
MITROFLOW AORTIC PERICARDIAL HEART VALVE WITH PHOSPHOLIPID REDUCTION TREATMENT, MODEL DL
Applicant location
Burnaby
Received
May 16, 2014
Decided
Jul 15, 2014
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol - OSB
Original approval
P060038

Device type

Device class
Class III

Every decision under product code LWR

FDA's approval statement

As written in FDA's record.

APPROVAL OF THE POST-APPROVAL STUDY PROTOCOL.

Source documents

Other decisions for Corcym Canada Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.